done some research on this

Having a read around, its really worth remembering that these machines are good for Medicare claims for the user. Thats a big deal in the credability and potential usage of the product. Each machine they roll out will produce revenues and they can keep rolling these things out for years. This is stacking up to be a leverage play IMO. The supplier of their hardware is going to float for something like $50m and IMI is their biggest customer. This is a global product, so stand bye. These guys can make big money on a per machine basis, so as the numbers build in sales, i would not be surprised to see this thing go nuts. IMI starts to roll out sales in the US and Asia and its all on for the biotech funds. Good luck.